Orbital radiotherapy for adult thyroid eye disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Rajendram, Rathie ^a   Bunce, C ^b   Lee, R W J ^b   Morley, S ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DATA BASE; DATA EXTRACTION; DATA SYNTHESIS; DIPLOPIA; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE PAIN; EYELID EDEMA; EYELID ERYTHEMA; HEALTH CARE COST; HUMAN; INTRAOCULAR PRESSURE; META ANALYSIS; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; OUTPATIENT CARE; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SAFETY; SENSITIVITY ANALYSIS; SHAM PROCEDURE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; VISUAL ACUITY;

EID: 44949214001     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007114     Document Type: Review

References (26)

1. Bahn 1993 Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. New England Journal of Medicine 1993;329(20):1468- 75.
2. Bahn 2003 Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. Journal of Clinical Endocrinology & Metabolism 2003;88(5):1939-46.
3. Bartalena 1998 Bartalena L, Marcocci C, Manetti L, Tanda ML, Dell'Unto E, Rocchi R, et al.Orbital radiotherapy for Graves' ophthalmopathy. Thyroid 1998;8(5):439-41.
4. Bartalena 2000 Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Reviews 2000;21(2):168-99.
5. Bartalena 2004 Bartalena L, Marcocci C, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy. Journal of Clinical Endocrinology & Metabolism 2004;89(1):13-4.
6. Cawood 2004 Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ 2004;329(7462):385-90.
7. Dickinson 2001 Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clinical Endocrinology 2001;55(3):283-303.
8. Feldon 2001 Feldon SE. Radiation therapy for Graves' ophthalmopathy: trick or treat?. Ophthalmology 2001;108(9):1521-2.
9. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
10. Gorman 2001 Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, et al.A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108(9):1523-34.
11. Kahaly 1988 Kahaly G, Beyer J. Immunosuppressant therapy of thyroid eye disease. Klinische Wochenschrift 1988;66(21):1049-59.
12. Marcocci 2001 Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, et al.Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology & Metabolism 2001;86(8):3562-7.
13. Marquez 2001 Marquez SD, Lum BL, McDougall IR, Katkuri S, Levin PS, MacManus M, et al.Long-termresults of irradiation for patients with progressive Graves' ophthalmopathy. International Journal of Radiation Oncology, Biology, Physics 2001;51(3):766-74.
14. Mourits 1989 Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology 1989;73(8):639-44.
15. Mourits 1997 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology 1997;47(1):9-14.
16. Mourits 2000 Mourits MP, van Kempen-Harteveld ML, Garcia Garcia MB, Koppeschaar HPF, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. The Lancet 2000;355(9214): 1505-9.
17. Perros 1993 Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clinical endocrinology 1993;38(4):367-72.
18. Perros 2006 The European Group of Graves' Orbitopathy, Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, et al.A questionnaire survey on the management of Graves' orbitopathy in Europe. European Journal of Endocrinology 2006;155(2):207-11.
19. Prummel 1989 Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al.Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. New England Journal of Medicine 1989;321(20):1353-9.
20. Prummel 1993 Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. The Lancet 1993;342(8877): 949-54.
21. Prummel 2004 Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, et al.Randomized Controlled Trial of Orbital Radiotherapy Versus Sham Irradiation in Patients with Mild Graves' Ophthalmopathy. Journal of Clinical Endocrinology & Metabolism 2004;89 (1):15-20.
22. Rundle 1945 Rundle F, Wilson C. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clinical Science 1945;5:177-194.
23. Terwee 2001 Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al.Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical Endocrinology 2001;54(3):391-8.
24. Terwee 2002 Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves' ophthalmopathy on health-related quality of life. European Journal of Endocrinology 2002;146(6): 751-7.
25. Werner 1977 Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. Journal of Clinical Endocrinology & Metabolism 1977;44(1):203-4.
26. Wiersinga 2006 The European Group on Graves' Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, et al.Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology 2006;155(3):387- 389.